Therefore, even if we take the more stringent inclusion criteria, the prescription rate of <2% in the current study is disconcertingly low, despite an increasing trend in the prescription of sac/val over the study period.
← all excerpts
Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants.
1
—
—